Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
healthcare system $380 billion annually
GLP-1s currently are taken in injections, but Eli Lilly is asking for Food and Drug Administration approval for a pill, orforglipron, that it has agreed to price at $149 for the lowest dose, and $399 for other doses
This level of weight loss is associated with a wide range of benefits, such as improved mobility, enhanced mental well-being, and reduced risks of chronic diseases associated with obesity
Canada is expected to register 37.6% CAGR from 2026 to 2036 as employer health plans seek maintenance support
Market Dynamics Driver - Strong Clinical Outcomes in Weight Loss & Glycemic Control GLP-1 receptor agonists are driving market growth due to their strong clinical outcomes in both weight loss and glycemic control
In addition, it has also been observed a SGLT2-i induced ACE2/ANG(1-7) pathway activation that may play a role in cardioprotection by competing with ANG II and AT1R (14)
